ARVEFAROVELLA THERAPEUTICS LTD.

About AROVELLA THERAPEUTICS LTD. (ARVEF)

AROVELLA THERAPEUTICS LTD. (ARVEF) is a N/A company headquartered in Preston, VA, Australia whose shares trade over-the-counter on the Pink tier.

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.

ARVEF key facts

Ticker symbol

ARVEF

Market tier

Pink

Headquarters

Preston, VA, Australia

Shares outstanding

941,423,356

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Explore more: Pink stocks · OTC stocks starting with A